(MENAFN- Straits Research)
Market Overview
The global arterial blood gas machine market size was valued at USD 1.49 billion in 2025 and is projected to grow from USD 1.60 billion in 2026 to USD 2.81 billion by 2034, registering a CAGR of 7.29% during the forecast period from 2026 to 2034. North America dominated the arterial blood gas machine market with a market share of 38.2% in 2025.
Blood gas analyzers are used in the diagnosis of several physiological parameters, such as blood vessel hemorrhage, diabetes, drug overdose, and shock testing, including hydrogen ion concentration, electrolytes, and oxygen concentration. Blood gas levels provide accurate results for acid-base balance, blood gases, and other electrolyte balance. ABG is helpful in the diagnosis of a variety of metabolic acid/base disorders, ventilation complications, and hypoxemia in the intensive care unit. Following the onset of therapy, repeat ABG may assess the efficacy of the intervention (e.g., when mechanical ventilation is performed for respiratory failure) and also indicate the degree of respiratory and renal compensation for a given acid/base condition.
ABGs are particularly helpful in operating theatre where acid/base status can dynamically change during cardiopulmonary bypass, one-lung ventilation, transplant surgery, and urological procedures. Its analysis is also helpful where tight control of partial CO2 pressure is necessary for better patient outcomes; for example, in neurosurgical cases where the impact of carbon dioxide on intracranial pressure (ICP) may be crucial. Additionally, blood gas testing is often recommended for patients assisted by the ventilator, undergoing respiratory distress evaluation to offer insights on the patient's oxygen level.
Download a Free Sample To learn more about this report,
Market Dynamics
Growing Demand for High Performance and Integrated Systems to Drive the Market Growth
An increasing number of patients admitted in intensive care units, emergency care centers, and operation theaters, growing demand for high performance and integrated systems, and increasing affordability of patients drive the market growth. The global geriatric population is growing at a significant rate, further rising the number of patients seeking medical care in emergency departments, critical care units, and operating rooms as they are highly susceptible to a myriad of diseases. The global geriatric population aged 65 and above is expected to grow from 7% in 2000 to 16% by 2050, as per the World Health Organization (WHO).
Technological Advancements in Arterial Blood Gas Machines
The arterial blood gas machine market's most prominent driver is the rapid innovations and advancements in technology. The development of innovative devices from the bench-top to portable, mobile, and elegant point-of-care devices provides an impetus to the market growth. In addition, the expanded test kit market integrates blood gas and electrolyte analysis features to include multiple electrolytes, bilirubin, creatinine, and single-sample blood urea nitrogen testing. For instance, Sphere Medical Ltd, a U.K. based company, developed a blood gas analyzer that includes an application-specific integrated circuit (ASIC) and a disposable sensor.
Novel Application of Arterial Blood Gas Machines
Increasing demand for high efficiency and integrated systems, suitable treatment in trauma centers and ICU, delivery of fast and credible results, and high turnaround time of blood gas analyzers drives the market growth. The ability of blood gas analyzers to integrate with electronic health/medical records (EHRs/EMRs) has improved the workflow and limited manual errors. Increasing application of ABG machines in surgical procedures, such as hypoventilation, endotracheal tube placement, and esophageal intubation, due to higher sensitivity, improved patient safety profile, and faster detection of respiratory insufficiency provides an impetus to the market growth.
Rising Prevalence of Cancer to Prompt the Need for Effective Blood Gas Machines
Globally, the healthcare expenditure for the treatment of chronic diseases, such as cancer and chronic respiratory diseases, has been witnessing a significant surge. Private organizations and governments are channelizing efforts to formulate favorable initiatives to reduce healthcare expenditure, which includes encouraging patients to undergo regular diagnostic examinations. As per the WHO, the global incidence of cancer was 14.1 million in 2012 and is projected to reach 23.6 million by 2030, further prompting the need for efficient blood gas machines.
Segmental Analysis
Portable Blood Gas Machines Segment to Dominate the Market
The portable blood gas machines segment held the largest market share in 2018 and is projected to dominate the market during the forecast period on account of its ability to render instantaneous test results and faster turnaround time. The segment's primary driver is the increasing demand for point-of-care blood gas machines.
Request Customization to receive a tailored report.
Umpteen Benefits Offered by Bench Top Abg to Drive the Segment Growth
The benchtop ABG segment leads the market on account of its increasing applications in umpteen hospital settings. Benchtop analyzers offer a range of benefits such as individual biosensor technology, broad test menu, and low cost of operation, further driving the segment growth.
Increasing Demand for Abg Machines in Icu's
The ICU segment holds the highest market share during the forecast period owing to the increasing number of patients admitted in intensive care units and emergency wards. Increasing demand of ABG machine to track the pH levels, carbon dioxide, and oxygen in the blood and determine the occurrence of medical conditions such as heart failure, kidney failure, chemical poisoning, drug overdose, and hemorrhage drives the segment growth.
Speak to an Analyst to discuss market opportunities.
Regional Analysis
Strong Presence of Domestic and International Players to Drive North America's Market Growth
North America dominates the arterial blood gas machines market as the region is backed by the presence of umpteen healthcare practitioners. Increasing patient awareness, availability of well-established healthcare infrastructure, and government support drive the regional market growth. As per the Centers for Disease Control and Prevention (CDC) report, in the U.S., around 1.7 million emergency department visits were recorded in 2017. The strong presence of domestic and international medical device manufacturers supplying ABG machines to both the developed and emerging markets provides an impetus to the regional market growth.
Unlock Regional Insights to access country-level data, & regional trends.
Rapid Product Development by Prominent Players to Drive Europe's Market Growth
Europe's arterial blood gas machines market is backed by the presence of prominent medical device companies and the growing geriatric population. Apart from this, increasing prevalence of cancer and other chronic disorders, rising public funding in healthcare, and favorable government initiatives provide an impetus to the market growth. Recently, Siemens Healthineers, a German-based medical device company, launched RAPID Point 500e Blood Gas Analyzer, a trusted instrument in Europe's endeavor, to combat COVID-19 and help address unprecedented demand for blood gas testing.
List of Key and Emerging Players in Arterial Blood Gas (ABG) Machine Market
Abbott Laboratories
Alere, Inc.
Bayer AG
Dalko Diagnostics
GE Healthcare
Instrumentation Laboratory
Nova Biomedical
Radiometer
Roche Diagnostics
Siemens Healthcare
Sphere Medical
Key Industry Developments
May 2026: Radiometer launched its next-generation ABL blood gas analyzer, featuring enhanced automation, faster turnaround time, and expanded connectivity to hospital laboratory information systems, improving critical care diagnostics.
March 2026: Siemens Healthineers introduced an upgraded epoc® Blood Analysis System with advanced wireless connectivity and expanded point-of-care testing capabilities for emergency and intensive care settings.
December 2025: Werfen expanded its GEM PremierTM blood gas analyzer portfolio by introducing new intelligent quality management features to improve workflow efficiency and analytical reliability in clinical laboratories.
September 2025: Nova Biomedical launched an enhanced version of its Stat Profile Prime® Plus blood gas analyzer, incorporating improved automation and expanded critical care testing parameters for hospitals and emergency departments.
Report Scope
Comments
No comment